Full publication of combination-therapy data is awaited, however interim analysis from the phase II COURAGE trial (NCT06299098) found 3.3% reduction in lean mass of obese patients treated with the combination of trevogrumab and semaglutide, compared with 6.5% reduction with semaglutide alone [70]
In the bones, GLP-1 promotes the activity of osteoblasts (the cells that build new bone) and suppresses the activity of osteoclasts (the resorptive cells responsible for cleaning out old or damaged bone)
Reuss DE, Habel A, Hagenlocher C, et al
Wilmot EG, Edwardson CL, Achana FA, Davies MJ, Gorely T, Gray LJ, et al
Naltrexone can lower seizure thresholds, contraindicate opioid medications, and may worsen mood in some patientsconsiderations that must be weighed against semaglutide's own side effect profile
F.MorcavalloA.et al (2013)